These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30780865)

  • 41. Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study.
    Franco JFDS; El Dib R; Agarwal A; Soares D; Milhan NVM; Albano LMJ; Kim CA
    Intractable Rare Dis Res; 2017 Aug; 6(3):183-190. PubMed ID: 28944140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation.
    Carbajal-Rodríguez LM; Pérez-García M; Rodríguez-Herrera R; Rosales HS; Olaya-Vargas A
    Heliyon; 2021 Aug; 7(8):e07740. PubMed ID: 34458603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
    Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
    Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valve surgery in a mucopolysaccharidosis type I patient: early prosthetic valve endocarditis.
    Rocha RV; Alvarez RJ; Bermudez CA
    Eur J Cardiothorac Surg; 2012 Feb; 41(2):448-9. PubMed ID: 21820914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study.
    Bitencourt FH; Vieira TA; Steiner CE; Neto JC; Boy R; Schwartz IVD
    Value Health Reg Issues; 2015 Dec; 8():99-106. PubMed ID: 29698178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
    Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
    Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report.
    Vasilevska L; Auzenbaha M; Grinfelde I; Skangale A
    Front Pediatr; 2022; 10():973193. PubMed ID: 36052356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II.
    Uttarilli A; Ranganath P; Matta D; Md Nurul Jain J; Prasad K; Babu AS; Girisha KM; Verma IC; Phadke SR; Mandal K; Puri RD; Aggarwal S; Danda S; Sankar VH; Kapoor S; Bhat M; Gowrishankar K; Hasan AQ; Nair M; Nampoothiri S; Dalal A
    Clin Genet; 2016 Dec; 90(6):496-508. PubMed ID: 27146977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mucopolysaccharidosis Type I in Mexico: Case-Based Review.
    Cantú-Reyna C; Vazquez-Cantu DL; Cruz-Camino H; Narváez-Díaz YA; Flores-Caloca Ó; González-Llano Ó; Araiza-Lozano C; Gómez-Gutiérrez R
    Children (Basel); 2023 Mar; 10(4):. PubMed ID: 37189891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mucopolysaccharidosis Type I.
    Kubaski F; de Oliveira Poswar F; Michelin-Tirelli K; Matte UDS; Horovitz DD; Barth AL; Baldo G; Vairo F; Giugliani R
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32188113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
    J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
    Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
    J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apparent allelism of the Hurler, Scheie, and Hurler/Scheie syndromes.
    Mueller OT; Shows TB; Opitz JM
    Am J Med Genet; 1984 Jul; 18(3):547-56. PubMed ID: 6433708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical features of Mexican patients with Mucopolysaccharidosis type I.
    Alonzo-Rojo A; García-Ortiz JE; Ortiz-Aranda M; Gallegos-Arreola MP; Figuera-Villanueva LE
    Genet Mol Res; 2017 Sep; 16(3):. PubMed ID: 28973713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Common antigenicity for two glycosidases.
    Kakavanos R; Lehn P; Callebaut I; Meikle PJ; Parkinson-Lawrence EJ; Hopwood JJ; Brooks DA
    FEBS Lett; 2006 Jan; 580(1):87-92. PubMed ID: 16359666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I.
    Sugiura K; Kubo T; Ochi Y; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Mol Genet Metab Rep; 2020 Dec; 25():100662. PubMed ID: 33101981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation.
    Arora RS; Mercer J; Thornley M; Tylee K; Wraith JE
    J Inherit Metab Dis; 2007 Oct; 30(5):821. PubMed ID: 17570076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I.
    Hurt SC; Vera MU; Le SQ; Kan SH; Bui Q; Dickson PI
    Mol Genet Metab Rep; 2024 Mar; 38():101036. PubMed ID: 38173710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
    Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
    Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. alpha-L-iduronidase therapy for mucopolysaccharidosis type I.
    Tolar J; Orchard PJ
    Biologics; 2008 Dec; 2(4):743-51. PubMed ID: 19707455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.